Clinical trial NCT06480656: Eccentric Cycling Exercise During Pulmonary Rehabilitation Pulmonary Vascular Disease
Official title: Eccentric Cycling Exercise During Pulmonary Rehabilitation in Pulmonary Vascular Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Eccentric Cycling Exercise
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2024-06-28
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Eccentric cycling allows high intensities with low metabolic costs. Therefore the aim of this project is to investigate whether ECC improves exercise capacity and possibly hemodynamics during prolonged rehabilitation programs in patients with PVD

Detailed description: Eccentric cycling exercise (ECC) allows training at low metabolic costs and may therefore be valuable for patients with pulmonary vascular disease (PVD). For these patients, regular exercise training has an evidence level 1A recommendation in the current guidelines. Exercise training during longer and regular periods provides chronic adaptation, for which ECC was recently found to have a greater effectiveness than CON by increasing muscle strength, hypertrophy, six-minute walking distance and furthermore, by increasing maximum oxygen uptake (V'O2max) especially in patients with chronic obstructive pulmonary disease (COPD), chronic left heart failure or coronary heart disease.

Furthermore, the investigators conducted an RCT in which the investigators exposed patients with PVD to ECC and concluded that ECC is a feasible and well-tolerated exercise modality for PVD patients with severely lower O2 demand and load to the right ventricle.

Therefore the aim of this project is to investigate whether ECC improves exercise capacity and possibly hemodynamics during prolonged rehabilitation programs in patients with PVD.

Eligibility criteria: Inclusion Criteria:

* Diagnosed with PVD, either PAH or CTEPH according to recent guidelines
* Stable medication for at least 1 month
* Age 18 to 85 years
* No resting hypoxemia (PaO2 \>7.3kPa)

Exclusion Criteria:

* Any co-morbidity that limits the patient to participate the full rehabilitation
* Enrollments in other trials with active treatments

Primary outcomes:
measure: peak exercise capacity
timeFrame: 3 weeks
Secondary outcomes:
measure: Peak oxygen uptake
timeFrame: 3 weeks
measure: ventilatory equivalent for CO2
timeFrame: 3 weeks
measure: Finger pulseoximetry
timeFrame: 3 weeks
measure: 6 minute walk distance
timeFrame: 3 weeks
measure: systolic pulmonary artery pressure
timeFrame: 3 weeks
measure: total pulmonary resistance
timeFrame: 3 weeks
measure: ventricular - pulmonary arterial coupling
timeFrame: 3 weeks
measure: cardiac output
timeFrame: 3 weeks
measure: Arterial partial pressure for oxygen
timeFrame: 3 weeks
measure: Arterial partial pressure for carbon dioxide
timeFrame: 3 weeks
measure: Arterial oxygen saturation
timeFrame: 3 weeks
measure: Arterial lactate concentration
timeFrame: 3 weeks
measure: Borg CR 10 for perceived dyspnea
timeFrame: 3 weeks
measure: Borg CR 10 for perceived leg fatigue
timeFrame: 3 weeks
measure: Visual analogue scale generell well being
timeFrame: 3 weeks
measure: Visual analogue scale dyspnea
timeFrame: 3 weeks
Other outcomes:
Locations:
city: Erlinsbach
country: Switzerland
facility: Rehabilitation clinic Barmelweid
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Pneumology
Study officials:
References: